FORT-1: Phase II/III Study of Rogaratinib Versus Chemotherapy in Patients With Locally Advanced or Metastatic Urothelial Carcinoma Selected Based on FGFR1 / 3 mRNA Expression.
Cora N SternbergDaniel P PetrylakJoaquim BellmuntHiroyuki NishiyamaAndrea NecchiHoward GurneyJae Lyun LeeMichiel S Van Der HeijdenEli RosenbaumNicolas PenelSee-Tong PangJian-Ri LiXavier García Del Muro SolansFlorence Joly LobbedezZsuzsanna PápaiWeichao BaoPeter EllinghausChengxing LuMitchell SiereckiSabine CoppietersKeiko NakajimaTatiane Cristine IshidaDavid I QuinnPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2022)
mRNA overexpression may be better predictors of rogaratinib response.